Literature DB >> 16744397

The influence of arginine upon the growth rate of a transplantable tumour in the mouse.

E Gilroy1.   

Abstract

Entities:  

Year:  1930        PMID： 16744397      PMCID： PMC1254498          DOI： 10.1042/bj0240589

Source DB:  PubMed          Journal:  Biochem J        ISSN： 0264-6021            Impact factor:   3.857


× No keyword cloud information.
  2 in total

1.  Feeding Experiments with Deficiencies in the Amino-acid supply: Arginine and Histidine as possible Precursors of Purines.

Authors:  H Ackroyd; F G Hopkins
Journal:  Biochem J       Date:  1916-12       Impact factor: 3.857

2.  Studies on the Metabolism of Arginine and Histidine: Part II. Arginine and Histidine as Precursors of Purines.

Authors:  C P Stewart
Journal:  Biochem J       Date:  1925       Impact factor: 3.857
  2 in total
  10 in total

1.  The effect of arginine upon the body weight of mice injected with thyroxine, and bearing the tumour M 63.

Authors:  E Gilroy
Journal:  Biochem J       Date:  1931       Impact factor: 3.857

2.  Comparison of the effects of arginine and thyroxine upon tumour growth-rate in the mouse.

Authors:  E Gilroy
Journal:  Biochem J       Date:  1930       Impact factor: 3.857

3.  Further observations upon the correlation between the arginine and vitamin B content of diets, and the effect of thyroxine upon tumour growth.

Authors:  E Gilroy
Journal:  Biochem J       Date:  1930       Impact factor: 3.857

4.  Avitaminosis B in relation to tumour growth.

Authors:  E Gilroy
Journal:  Biochem J       Date:  1930       Impact factor: 3.857

5.  A study of the physiological value of α-amino acids during the early periods of growth and differentiation.

Authors:  F Gudernatsch; O Hoffman
Journal:  Wilhelm Roux Arch Entwickl Mech Org       Date:  1936-10

6.  Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.

Authors:  Tawnya L Bowles; Randie Kim; Joseph Galante; Colin M Parsons; Subbulakshmi Virudachalam; Hsing-Jien Kung; Richard J Bold
Journal:  Int J Cancer       Date:  2008-10-15       Impact factor: 7.396

Review 7.  Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges.

Authors:  Melissa M Phillips; Michael T Sheaff; Peter W Szlosarek
Journal:  Cancer Res Treat       Date:  2013-12-31       Impact factor: 4.679

8.  Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.

Authors:  Dong-Joo Cheon; Ann E Walts; Jessica A Beach; Jenny Lester; John S Bomalaski; Christine S Walsh; W Ruprecht Wiedemeyer; Beth Y Karlan; Sandra Orsulic
Journal:  J Pathol Clin Res       Date:  2014-11-05

9.  Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.

Authors:  Emma Beddowes; James Spicer; Pui Ying Chan; Ramsay Khadeir; Javier Garcia Corbacho; Dimitra Repana; Jeremy P Steele; Peter Schmid; Teresa Szyszko; Gary Cook; Monica Diaz; Xiaoxing Feng; Amanda Johnston; Jim Thomson; Michael Sheaff; Bor-Wen Wu; John Bomalaski; Simon Pacey; Peter W Szlosarek
Journal:  J Clin Oncol       Date:  2017-04-07       Impact factor: 44.544

10.  Epithelial argininosuccinate synthetase is dispensable for intestinal regeneration and tumorigenesis.

Authors:  Jonathan H M van der Meer; Ruben J de Boer; Bartolomeus J Meijer; Wouter L Smit; Jacqueline L M Vermeulen; Sander Meisner; Manon van Roest; Pim J Koelink; Evelien Dekker; Theodorus B M Hakvoort; Jan Koster; Lukas J A C Hawinkels; Jarom Heijmans; Eduard A Struijs; Marja A Boermeester; Gijs R van den Brink; Vanesa Muncan
Journal:  Cell Death Dis       Date:  2021-10-01       Impact factor: 8.469
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.